List of CD20 monoclonal antibodies - Drugs.com
WebWhat are CD20 monoclonal antibodies? Monoclonal antibodies used in immunotherapy are produced artificially from a cell clone therefore consist of a single type of …
Next-generation anti-CD20 monoclonal antibodies in …
WebNov 16, 2017 · Understanding how newer anti-CD20 mAbs compare with rituximab in terms of efficacy, safety, convenience, and cost is important for guiding future management of anti-CD20 mAb therapy in autoimmune diseases. Keywords: Anti-CD20, B cell, Multiple sclerosis, Rheumatoid arthritis, Systematic lupus erythematosus.
Efficacy and safety of new anti-CD20 monoclonal antibodies …
WebFeb 5, 2021 · Scientific Reports - Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and...
Anti-CD20 monoclonal antibodies: reviewing a revolution - PMC
WebSep 6, 2018 · In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab. KEYWORDS: Monoclonal antibody, CD20, rituximab, obinutuzumab, immunotherapy, lymphoma.
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on …
WebOct 20, 2020 · Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was approved in March 2017 by the Food and Drug Administration (FDA) and is also the first proven therapy to reduce disability progression in primary progressive MS.
Is there a role for anti-CD20 antibodies in CLL?
WebDec 10, 2021 · Anti-CD20 monoclonal antibodies (mAbs) have revolutionized the treatment of chronic lymphocytic leukemia (CLL) by improving survival of patients with CLL in conjunction with chemotherapy.
Anti-CD20 therapies for multiple sclerosis: current status and …
WebAug 11, 2021 · Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. Review. Published: 11 August 2021. Volume 269 , pages 1316–1334, ( 2022 ) Cite this article. Download PDF. Monica Margoni, Paolo Preziosa, Massimo Filippi & Maria A. Rocca. 13k Accesses. 45 Citations. 8 Altmetric. Explore all metrics. Abstract.
Anti-CD20 therapies for multiple sclerosis: current status and …
WebThe demonstration of the strong efficacy and good safety profile of selective B-cell-depleting therapies (such as anti-CD20 monoclonal antibodies) has significantly expanded the therapeutic scenario for both relapsing and progressive MS patients with the identification of a new therapeutic target.
Anti-CD20 treatment for B-cell malignancies: current status
WebOf the novel anti-CD20 antibodies, only obinutuzumab has shown consistently improved efficacy over rituximab in randomized pivotal trials in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. The Phase 3 GALLIUM trial demonstrated significant improvements in progression-free survival wi …
CD20 - Wikipedia
WebCD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B …
Skip to content